Want to see HK:2192 full AI Analyst Report?
Top Page
Medlive Technology Co., Ltd.
(2192)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$7.00
▼(-8.74% Downside)
Action:Upgraded
Date:08/07/26
The score is primarily supported by strong profitability and an exceptionally low-debt balance sheet, which reduces financial risk. This is tempered by the 2025 revenue decline and only moderate/volatile cash conversion. Technicals show improving near-term momentum but a still-weak longer-term trend, while valuation and dividend yield look reasonable.
Positive Factors
High Profitability
Very high gross and net margins indicate that Medlive’s platform-based services retain substantial value after direct and operating costs. If maintained, this profitability can support reinvestment in medical content, professional tools, and customer engagement while providing resilience against moderate revenue pressure.
Negative Factors
Revenue Contraction
The sharp 2025 revenue reversal weakens confidence that earlier expansion can continue consistently. Because Medlive monetizes services for life-science customers and healthcare professionals, a sustained top-line decline could reduce operating scale, constrain investment capacity, and make future earnings growth less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Very high gross and net margins indicate that Medlive’s platform-based services retain substantial value after direct and operating costs. If maintained, this profitability can support reinvestment in medical content, professional tools, and customer engagement while providing resilience against moderate revenue pressure.
Read all positive factors
Medlive Technology Co., Ltd. (2192) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.81B
Dividend Yield4.83%
Average Volume (3M)490.55K
Price to Earnings (P/E)12.0
Beta (1Y)1.35
Revenue Growth6.47%
EPS Growth8.10%
CountryHK
Employees713
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.46
Shares Outstanding740,274,500
10 Day Avg. Volume476,903
30 Day Avg. Volume490,551
Financial Highlights & Ratios
PEG Ratio4.16
Price to Book (P/B)1.32
Price to Sales (P/S)10.00
P/FCF Ratio52.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.75Price Target Upside27.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.44
Revenue Forecast (FY)HK$686.11M
Medlive Technology Co., Ltd. Business Overview & Revenue Model
Company Description
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers ...
How the Company Makes Money
Medlive generally makes money by monetizing its online medical platforms through (1) services provided to pharmaceutical and medical device companies and other life-science industry customers, where it offers digital marketing, physician engagemen...
Medlive Technology Co., Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
92
Very Positive
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 645.32M | 642.15M | 558.46M | 412.00M | 314.05M | 284.44M |
| Gross Profit | 395.63M | 385.44M | 327.22M | 251.34M | 212.74M | 200.73M |
| EBITDA | 216.03M | 188.44M | 133.04M | 262.86M | 144.56M | 76.61M |
| Net Income | 340.54M | 334.34M | 315.15M | 242.30M | 117.32M | 40.62M |
Balance Sheet | ||||||
| Total Assets | 5.04B | 5.16B | 5.11B | 4.89B | 4.60B | 4.12B |
| Cash, Cash Equivalents and Short-Term Investments | 2.66B | 3.72B | 4.15B | 4.40B | 4.22B | 3.91B |
| Total Debt | 6.43M | 10.11M | 22.63M | 8.19M | 11.26M | 13.17M |
| Total Liabilities | 189.90M | 230.01M | 253.56M | 248.61M | 171.31M | 143.37M |
| Stockholders Equity | 4.80B | 4.87B | 4.80B | 4.60B | 4.40B | 3.95B |
Cash Flow | ||||||
| Free Cash Flow | 271.32M | 121.70M | 87.44M | 69.34M | 69.70M | 42.47M |
| Operating Cash Flow | 273.45M | 134.54M | 108.32M | 101.87M | 77.19M | 44.43M |
| Investing Cash Flow | -149.15M | 220.68M | 111.02M | -634.95M | -3.59B | -50.54M |
| Financing Cash Flow | -214.78M | -201.45M | -197.89M | -133.13M | -22.38M | 3.79B |
Medlive Technology Co., Ltd. Technical Analysis
Neutral
7.67
Price Trends
6.87
Negative
7.05
Negative
8.00
Negative
Market Momentum
-0.14
Negative
46.57
Neutral
50.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2192, the sentiment is Neutral. The current price of 7.67 is above the 20-day moving average (MA) of 6.49, above the 50-day MA of 6.87, and below the 200-day MA of 8.00, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 46.57 is Neutral, neither overbought nor oversold. The STOCH value of 50.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2192.
Medlive Technology Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.81B | 12.01 | 7.05% | 4.83% | 6.47% | 8.10% | |
65 Neutral | HK$49.81B | 6.03 | 8.33% | 4.95% | 2.78% | 7.71% | |
61 Neutral | HK$64.18B | 12.76 | 6.21% | 5.91% | 8.02% | -17.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$592.92M | 10.85 | 7.70% | 6.26% | 14.25% | 0.83% | |
41 Neutral | HK$360.66M | -5.19 | -273.18% | ― | 5.52% | 56.54% | |
39 Underperform | HK$551.31M | -6.20 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:2192
Medlive Technology Co., Ltd.
6.50
-4.00
-38.08%
HK:0673
China Health Group
0.26
-0.24
-48.00%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.05
-0.52
-4.54%
HK:1099
Sinopharm Group Co
15.96
-2.44
-13.28%
HK:1931
IVD Medical Holding Limited
0.34
-6.61
-95.11%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.49
0.38
7.46%
Medlive Technology Co., Ltd. Corporate Events
Medlive Technology Launches Discretionary Share Buyback Under 2026 Mandate
Oct 26, 2026
Medlive Technology Co., Ltd. has begun repurchasing its shares on the open market under a general mandate approved by shareholders in May 2026, using internal funds. The board believes the current share price undervalues the company’s long-t...
Medlive Technology Posts Modest Interim Revenue Growth on Solid Precision Marketing Performance
Aug 28, 2026
Medlive Technology Co., Ltd. reported interim unaudited revenue of RMB315.2 million for the six months ended 30 June 2026, a modest 1.0% year-on-year increase, driven primarily by its precision marketing and corporate solutions segment, which cont...
Medlive Technology Declares Interim Cash Dividend for First Half of 2026
Aug 28, 2026
Medlive Technology Co., Ltd. has declared an interim ordinary cash dividend of RMB 0.1309 per share for the six months ended 30 June 2026, equivalent to HKD 0.1513 per share based on an exchange rate of RMB 1 to HKD 1.1556. The dividend relates to...
Medlive sets August board meeting to approve interim results and consider dividend
Aug 11, 2026
Medlive Technology Co., Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The board will also consider the declaration of an interim dividend, signaling...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.